{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:11Z","timestamp":1781639711751,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Active surveillance (AS) is the standard approach for managing ISUP 1 prostate cancer (PCa), ensuring oncological safety while minimizing overtreatment. However, AS protocols vary significantly. This study assessed a structured AS protocol incorporating PSA kinetics, multiparametric MRI (mpMRI), and targeted biopsies to identify predictors of treatment transition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 89 patients with ISUP 1 PCa managed with AS between 2010 and 2024. Inclusion criteria were PSA\u2009&lt;\u200910\u00a0ng\/mL and\u2009\u2264\u20092 positive biopsy cores with\u2009\u2264\u200950% tumor involvement per core. Patients underwent regular PSA testing, mpMRI, and risk-adapted biopsies. Outcomes included treatment conversion, progression predictors, and the role of mpMRI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median follow-up was 52.8\u00a0months. PSA was monitored at a median interval of 4.8\u00a0months, and mpMRI every 15.7\u00a0months (median). At diagnosis, 68.5% underwent mpMRI, with PIRADS 4 as the most frequent. During AS, 66.3% underwent at least one re-biopsy, most commonly triggered by PSA progression (73%). Treatment was initiated in 37.1% after a median of 37.9\u00a0months due to PSA progression (54.5%), mpMRI changes (21.2%), combined PSA\/mpMRI findings (6.1%), histological upgrading (9.1%), or patient preference (3%). Treatments included radical prostatectomy, EBRT or LDR brachytherapy. Among these patients, no PSA persistence was observed; biochemical recurrence occurred in 6.1%, metastases in 4.0%, and overall mortality in 4.5%, with no PCa-specific deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A structured, risk-adapted AS protocol using PSA kinetics and mpMRI enabled personalized management and timely detection of progression. These findings support the standardization of AS protocols, which should be validated in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06441-9","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:18:14Z","timestamp":1772633894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3241-3183","authenticated-orcid":false,"given":"Giulia","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8260-9501","authenticated-orcid":false,"given":"Nastasiia","family":"Artamonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4775-948X","authenticated-orcid":false,"given":"Mona","family":"Kafka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-5746","authenticated-orcid":false,"given":"Isabel","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"6441_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.05.008","author":"A Alberti","year":"2024","unstructured":"Alberti A, Nicoletti R, Castellani D, Yuan Y, Maggi M, Dibilio E, Resta GR, Makrides P, Sessa F, Sebastianelli A, Serni S, Gacci M, De Nunzio C, Teoh JYC, Campi R (2024) Patient-reported outcome measures and experience measures after active surveillance versus radiation therapy versus radical prostatectomy for prostate cancer: a systematic review of prospective comparative studies. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.05.008","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"6441_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","volume":"63","author":"M Bul","year":"2013","unstructured":"Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, Van Der Schoot DK, Cornel EB, Conti GN, Boev\u00e9 ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Str\u00f6lin P, Van Muilekom E, Schr\u00f6der FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597\u2013603. https:\/\/doi.org\/10.1016\/j.eururo.2012.11.005","journal-title":"Eur Urol"},{"key":"6441_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.38039","author":"G Ciccone","year":"2023","unstructured":"Ciccone G, De Luca S, Oderda M, Munoz F, Krengli M, Allis S, Baima CG, Barale M, Bartoncini S, Beld\u00ec D, Bellei L, Bellissimo AR, Bernardi D, Biamino G, Billia M, Borsa R, Cante D, Castelli E, Cattaneo G, Bertetto O (2023) Patient and context factors in the adoption of active surveillance for low-risk prostate cancer. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.38039","journal-title":"JAMA Netw Open"},{"key":"6441_CR6","doi-asserted-by":"publisher","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, \u2026 Tilki D (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 86(2):148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"issue":"2","key":"6441_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/bju.16727","volume":"136","author":"II de Vos","year":"2025","unstructured":"de Vos II, Marenghi C, Badenchini F, Boev\u00e9 ER, Lozano-Uru\u00f1uela F, Graefen M, Rannikko AS, Staerman F, Sugimoto M, Kato T, Somford DM, Frydenberg M, Bangma CH, Remmers S, Roobol MJ (2025) Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU Int 136(2):245\u2013253. https:\/\/doi.org\/10.1111\/bju.16727","journal-title":"BJU Int"},{"issue":"7","key":"6441_CR5","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.3390\/curroncol29070400","volume":"29","author":"JE Deluce","year":"2022","unstructured":"Deluce JE, Cardenas L, Lalani A-K, Maleki Vareki S, Fernandes R (2022) Emerging biomarker-guided therapies in prostate cancer. Curr Oncol (Toronto, Ont) 29(7):5054\u20135076. https:\/\/doi.org\/10.3390\/curroncol29070400","journal-title":"Curr Oncol (Toronto, Ont)"},{"issue":"17","key":"6441_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/nejmoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Young GJ, Walsh EI, Bryant RJ, Bollina P, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Neal DE (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England J Med 388(17):1547\u20131558. https:\/\/doi.org\/10.1056\/nejmoa2214122","journal-title":"New England J Med"},{"issue":"1","key":"6441_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/tau.2017.12.24","volume":"7","author":"N Kinsella","year":"2018","unstructured":"Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, Van Hemelrijck M (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7(1):83\u201397. https:\/\/doi.org\/10.21037\/tau.2017.12.24","journal-title":"Transl Androl Urol"},{"issue":"3","key":"6441_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272\u2013277. https:\/\/doi.org\/10.1200\/JCO.2014.55.1192","journal-title":"J Clin Oncol"},{"issue":"1","key":"6441_CR10","doi-asserted-by":"publisher","first-page":"12002","DOI":"10.1038\/s41598-021-91310-3","volume":"11","author":"H Lee","year":"2021","unstructured":"Lee H, Byun S-S, Lee SE, Hong SK (2021) Impact of poor glycemic control upon clinical outcomes after radical prostatectomy in localized prostate cancer. Sci Rep 11(1):12002. https:\/\/doi.org\/10.1038\/s41598-021-91310-3","journal-title":"Sci Rep"},{"issue":"5","key":"6441_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.eururo.2021.05.024","volume":"80","author":"AR Padhani","year":"2021","unstructured":"Padhani AR, Rouvi\u00e8re O, Schoots IG (2021) Magnetic resonance imaging for tailoring the need to biopsy during follow-up for men on active surveillance for prostate cancer. Eur Urol 80(5):564\u2013566. https:\/\/doi.org\/10.1016\/j.eururo.2021.05.024","journal-title":"Eur Urol"},{"issue":"12","key":"6441_CR12","first-page":"4445","volume":"31","author":"P Pepe","year":"2011","unstructured":"Pepe P, Aragona F (2011) PCA3 score vs PSA free\/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res 31(12):4445\u20134449","journal-title":"Anticancer Res"},{"issue":"3","key":"6441_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4081\/aiua.2022.3.270","volume":"94","author":"P Pepe","year":"2022","unstructured":"Pepe P, Pepe L, Pennisi M, Fraggetta F (2022) Confirmatory transperineal saturation prostate biopsy combined with mpMRI decrease the reclassification rate in men enrolled in active surveillance: our experience in 100 men submitted to eight-years scheduled biopsy. Arch Ital Urol Androl 94(3):270\u2013273. https:\/\/doi.org\/10.4081\/aiua.2022.3.270","journal-title":"Arch Ital Urol Androl"},{"key":"6441_CR14","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2023.11322","author":"P Pepe","year":"2023","unstructured":"Pepe P, Pepe L, Tamburo M, Marletta G, Pennisi M, Fraggetta F (2023) 68Ga-PSMA PET\/CT evaluation in men enrolled in prostate cancer active surveillance. Arch Ital Urol Androl. https:\/\/doi.org\/10.4081\/aiua.2023.11322","journal-title":"Arch Ital Urol Androl"},{"issue":"6","key":"6441_CR15","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/j.clgc.2020.04.006","volume":"18","author":"M Roscigno","year":"2020","unstructured":"Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, Naspro R, Nicolai M, La Croce G, Aljoulani M, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF (2020) The use of multiparametric magnetic resonance imaging for follow-up of patients included in active surveillance protocol. Can PSA density discriminate patients at different risk of reclassification? Clin Genitourin Cancer 18(6):e698\u2013e704. https:\/\/doi.org\/10.1016\/j.clgc.2020.04.006","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"6441_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1185\/03007995.2013.873398","volume":"30","author":"N Shore","year":"2014","unstructured":"Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, Lewine N, Gustavsen G, Pothier K, Brawer MK (2014) Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin 30(4):547\u2013553. https:\/\/doi.org\/10.1185\/03007995.2013.873398","journal-title":"Curr Med Res Opin"},{"key":"6441_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17224-w","author":"D Sypre","year":"2022","unstructured":"Sypre D, Pignot G, Touzani R, Marino P, Walz J, Rybikowski S, Maubon T, Branger N, Salem N, Mancini J, Gravis G, Bendiane MK, Bouhnik AD (2022) Impact of active surveillance for prostate cancer on the risk of depression and anxiety. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-022-17224-w","journal-title":"Sci Rep"},{"issue":"6","key":"6441_CR18","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/j.juro.2015.03.043","volume":"193","author":"SS Taneja","year":"2015","unstructured":"Taneja SS (2015) Re: Five-year nationwide follow-up study of active surveillance for prostate cancer. J Urol 193(6):1981\u20131983. https:\/\/doi.org\/10.1016\/j.juro.2015.03.043","journal-title":"J Urol"},{"key":"6441_CR19","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.14694\/edbk_159244","volume":"36","author":"JJ Tosoian","year":"2016","unstructured":"Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM (2016) Active surveillance of prostate cancer: use, outcomes, imaging, and diagnostic tools. Am Soc Clin Oncol Educ Book 36:e235\u2013e245. https:\/\/doi.org\/10.14694\/edbk_159244","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"6441_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00345-021-03622-8","volume":"40","author":"CH Walker","year":"2022","unstructured":"Walker CH, Marchetti KA, Singhal U, Morgan TM (2022) Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. World J Urol 40(1):35\u201342. https:\/\/doi.org\/10.1007\/s00345-021-03622-8","journal-title":"World J Urol"},{"issue":"1","key":"6441_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MOU.0000000000000133","volume":"25","author":"JT Wei","year":"2015","unstructured":"Wei JT (2015) Urinary biomarkers for prostate cancer. Curr Opin Urol 25(1):77\u201382. https:\/\/doi.org\/10.1097\/MOU.0000000000000133","journal-title":"Curr Opin Urol"},{"issue":"4","key":"6441_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","volume":"81","author":"PPM Willemse","year":"2022","unstructured":"Willemse PPM, Davis NF, Grivas N, Zattoni F, Lardas M, Briers E, Cumberbatch MG, De Santis M, Dell\u2019Oglio P, Donaldson JF, Fossati N, Gandaglia G, Gillessen S, Grummet JP, Henry AM, Liew M, MacLennan S, Mason MD, Moris L, Dell\u2019Oglio P, Plass K, O\u2019Hanlon S, Omar MI, Oprea-Lager DE, Pang KH, Paterson CC, Ploussard G, Rouvi\u00e8re O, Schoots IG, Tilki D, van den Bergh RCN, den Van Broeck T, van der Kwast TH, van der Poel HG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TBL (2022) Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy. Eur Urol 81(4):337\u2013346. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.007","journal-title":"Eur Urol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06441-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:21:26Z","timestamp":1781637686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06441-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6441"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06441-9","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical University of Innsbruck (vote number: 1296\/2923).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study does not include any individual person\u2019s data in any form.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"57"}}